Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Authors||Dent, R. et al.|
|Title||Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A|
|Abstract Text||Background: In the randomized phase II LOTUS trial [Kim, Lancet Oncol 2017], adding IPAT to PAC improved progression-free survival (PFS), with a more pronounced effect in patients with PIK3CA/AKT1/PTEN-altered tumors. This effect provided the rationale for the biomarker-selected IPATunity130 phase III trial. Here we report primary results from Cohort A in aTNBC. Patients and methods: In Cohort A of this pivotal phase III trial (NCT03337724), eligible patients had PIK3CA- and/or AKT1- and/or PTEN-altered measurable aTNBC, ECOG performance status 0/1, were appropriate candidates for taxane monotherapy, and had received no prior chemotherapy for aTNBC. Patients were randomized 2:1 to receive either oral IPAT 400 mg or PBO (days 1-21), both combined with IV PAC 80 mg/m2 (days 1, 8, & 15). Cycles were repeated every 28 days until disease progression, unacceptable toxicity, or patient withdrawal. Stratification factors were: prior (neo)adjuvant chemotherapy (yes vs no); geographic region (Asia-Pacific vs Europe vs North America vs rest of world); and tumor alteration status (PIK3CA/AKT1-activating mutation vs PTEN alteration without PIK3CA/AKT1-activating mutation). The primary endpoint was investigator-assessed PFS; secondary endpoints included overall survival (OS; key secondary), objective response rate (ORR), duration of response, clinical benefit rate (CBR), patient-reported outcomes, and safety. Results: Between 6 Feb 2018 and 8 Apr 2020, 255 patients were enrolled, of whom 51% had received (neo)adjuvant chemotherapy and 59% had visceral disease; 51% had PIK3CA/AKT1-activating mutations and the remaining 49% had PTEN alterations (without PIK3CA/AKT1-activating mutations). At the clinical cut-off date (7 May 2020), median duration of follow-up was 8.3 months (range 0-26.8 months) and 33% of patients remained on treatment. Mean duration of PAC was similar in the two groups (5.5 vs 5.4 months in the IPAT vs PBO arms, respectively). There was no difference in PFS between treatment groups overall (Table) nor in any prespecified subgroups. OS results are immature (deaths in 20% of patients). Similar proportions of patients in the IPAT and PBO arms experienced grade ≥3 adverse events (AEs) (46% vs 44%, respectively), fatal AEs (1% vs 1%), and AEs leading to discontinuation of any treatment (14% vs 15%), although AEs leading to dose reduction of any treatment were more common with IPAT (35% vs 14%). The most common AEs (any grade) were diarrhea (80% vs 31%; grade ≥3 9% vs 2%), alopecia (46% vs 44%), and nausea (36% vs 23%). Conclusions: In contrast to results from the phase II LOTUS trial, this trial showed no PFS improvement with the addition of IPAT to first-line PAC in patients with PIK3CA/AKT1/PTEN-altered aTNBC. Biomarker analyses are ongoing to evaluate potential markers of IPAT benefit. Safety was consistent with previously reported results for this combination.|
|Molecular Profile||Treatment Approach|
|Gene Name||Source||Synonyms||Protein Domains||Gene Description||Gene Role|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gene||Variant||Impact||Protein Effect||Variant Description||Associated with drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PIK3CA act mut||triple-receptor negative breast cancer||no benefit||Ipatasertib + Paclitaxel||Phase III||Actionable||In a Phase III trial (IPATunity 130), the addition of Ipatasertib (GDC-0068) to treatment with Abraxane (paclitaxel) did not result in improved progression-free survival in patients with triple-negative breast cancer harboring PIK3CA and/or AKT activating mutations or PTEN alterations, with a median PFS of 7.4 months with Ipatasertib (GDC-0068) plus Abraxane (paclitaxel) vs. 6.1 months with placebo plus Abraxane (paclitaxel) (SABCS Meeting 2020, Abstract GS3-04; NCT03337724).||detail...|
|PTEN inact mut||triple-receptor negative breast cancer||no benefit||Ipatasertib + Paclitaxel||Phase III||Actionable||In a Phase III trial (IPATunity 130), the addition of Ipatasertib (GDC-0068) to treatment with Abraxane (paclitaxel) did not result in improved progression-free survival in patients with triple-negative breast cancer harboring PIK3CA and/or AKT activating mutations or PTEN alterations, with a median PFS of 7.4 months with Ipatasertib (GDC-0068) plus Abraxane (paclitaxel) vs. 6.1 months with placebo plus Abraxane (paclitaxel) (SABCS 2020, Abstract GS3-04; NCT03337724).||detail...|